Condition
Influenza B Virus Infection
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 3 (1)
P 4 (1)
Trial Status
Completed2
Enrolling By Invitation1
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06401720Enrolling By Invitation
Age Related Differences in Respiratory Immune Responses in Influenza Virus Infection
NCT00844155Not ApplicableWithdrawn
Study of the Relative Oral Bioavailability of the Antiflu Medicine Oseltamivir in the Intensive Care Unit
NCT02250274Phase 4Completed
Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents
NCT01459081Phase 3Completed
Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China
Showing all 4 trials